A NEW ERA OF VACCINES

The Novavax COVID-19 Vaccine, Adjuvanted is now available in
the U.S. under Emergency Use Authorization for primary vaccination
for individuals 12+, and as a first booster dose for adults

See conditions of use

CDC Vaccine Finder

Latest press release on vaccine candidates

View press releases

COVID-19 vaccine research updates

Novavax COVID-19 vaccine (recombinant, adjuvanted) is now conditionally authorized in several regions

Latest update

Novavax information for:

General public

Medical professionals

Investors

Career seekers

Novavax information for:

NEWS & MEDIA

Novavax Announces Launch of Global Vaccine Education Programs

We focus on this so you can focus on that

Full press release

NEWS & MEDIA

Current Protocol for Phase 3 Clinical Trial of NVX-CoV2373 in the U.S. and Mexico

Full press release

Novavax's Investor Hub

Visit our Investor Hub to access investor resources and information on upcoming and past events. Sign up to receive notifications for investor updates, such as upcoming events and webcasts, daily closing stock price, SEC filings, and press releases.